Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp is advancing its orphan lung pipeline, which is expected to contribute to long-term diversification and growth for the company. The management's focus on enhanced education and marketing strategies is anticipated to improve product uptake, particularly for Afrezza and Tyvaso DPI, which are gaining market share in their respective indications. Furthermore, Tyvaso DPI's potential for robust royalty revenues from the idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) segments presents favorable financial opportunities, driving positive outlooks for the company.

Bears say

MannKind Corp faces a negative outlook primarily due to the vulnerabilities in its intellectual property protections, which could lead to diminished competitive advantages and market share erosion. Additionally, ongoing issues with pricing adjustments for its products suggest challenges in maintaining profitability amid competitive pressures from well-capitalized rivals with established offerings. Delays in regulatory approvals or adverse trial outcomes related to key therapies, such as MNKD-102 and MNKD-201, further exacerbate concerns over future commercialization potential and market opportunities.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.